ReviewCurrent diabetes reports2009
Dyslipidemia following kidney transplantation: diagnosis and treatment.
Review in Current diabetes reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 54 citations in OpenAlex.
- Association between the atherogenic index of plasma and prognosis in kidney transplant recipients: a retrospective cohort study.International urology and nephrology · 2026Article
- Association of remnant cholesterol with long-term outcomes in kidney transplant recipients: a retrospective cohort study.Lipids in health and disease · 2026Article
- Finerenone in kidney transplantation: an underinvestigated agent: review of available evidence, existing gaps, and future directions.Clinical transplantation and research · 2026Review
- Early Post-Transplant Changes in Lipoprotein(a), Autotaxin Activity, and Lipid Profile: A Prospective Observational Study of Tacrolimus-Treated Kidney Transplant Recipients in Poland.International journal of molecular sciences · 2026Observational
- Voclosporin ameliorates proteinuria in a model of non-inflammatory glomerular disease.BMC nephrology · 2026Article
- Kidney transplantation and statins effects on dyslipidemia in kidney transplant recipients.Annals of medicine and surgery (2012) · 2025Article
- Review
- High-Density Lipoprotein Particles and Torque Teno Virus in Stable Outpatient Kidney Transplant Recipients.Viruses · 2024Article
- Haematological Drugs Affecting Lipid Metabolism and Vascular Health.Biomedicines · 2022Review
- Evaluation of Changes Over Time in the Drug Burden and Medication Regimen Complexity in ESRD Patients Before and After Renal Transplantation.Kidney international reports · 2021Article
- HLA-G14bp ins/del polymorphism and post-transplant weight gain in kidney transplantation: potential implications beyond tolerance.BMC nephrology · 2020Article
- The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?Advances in chronic kidney disease · 2020Review
- Ratio of triglyceride to high-density lipoprotein cholesterol and risk of major cardiovascular events in kidney transplant recipients.Clinical and experimental nephrology · 2019Observational
- Review
- [Correlation of blood concentration of tacrolimus with serum cystatin C in renal transplant recipients and effect of tacrolimus on glucose and lipid metabolism].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2017Article
- Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation.Therapeutics and clinical risk management · 2017Article
- Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism.Nature communications · 2016Article
- Dyslipidemia after kidney transplantation and correlation with cyclosporine level.Nephro-urology monthly · 2013Article
- Lipid parameters, doses and blood levels of calcineurin inhibitors in renal transplant patients.Indian journal of clinical biochemistry : IJCB · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid abnormalities are a common complication of kidney transplantation, occurring in up to 60% of patients. In fact, impairment of lipid metabolism is often present before renal transplantation due to the uremic state. After transplantation and recovery of renal function, lipid disturbances usually persist but show a different profile due to the various effects of immunosuppressive drugs on lipid metabolism. Actually, steroids, calcineurin inhibitors, and mammalian target of rapamycin inhibitors usually lead to quantitative and qualitative abnormalities of very low-density, low-density, and high-density lipoproteins. As cardiovascular diseases remain the leading cause of death in renal transplant recipients, management of dyslipidemia and other traditional risk factors, such as smoking, arterial hypertension, diabetes mellitus, and obesity, is of great importance to prevent cardiovascular complications and chronic allograft dysfunction. This review addresses the causes of dyslipidemia, the role of immunosuppressive drugs, and current recommendations to manage lipid disorders in renal transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.